Implications of Heterotypic Cell Fusion in Cancer
Hybrid cancer-immune cells in blood offer a new fingerprint for early cancer detection and predicting treatment resistance beyond traditional tumor DNA.
This review establishes tumor-immune hybrid cells arising from cancer-macrophage cell fusion as a novel class of circulating cancer biomarkers in peripheral blood, with published clinical utility for early cancer detection, metastatic risk stratification, and treatment resistance across multiple cancer types. CHCs represent a distinct liquid biopsy modality beyond ctDNA/cfDNA with potentially unique information on metastatic biology.
What the study was
- Study design
- Narrative review (book chapter)
- Population
- Cancer patients (various types)
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Adv Exp Med Biol
Why it surfaced
Novel liquid biopsy modality (CHCs) distinct from ctDNA; sentinel scan discovery; potential for early cancer detection and metastatic risk.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.